Education
About Us
Working with TipRanks
Follow Us
Zai Lab (ZLAB)
NASDAQ:ZLAB
ZLAB Stock Chart & Stats
$19.97
-$1.34(-5.19%)
At close: 4:00 PM EST
$19.97
-$1.34(-5.19%)
Day’s Range― - ―
52-Week Range$19.51 - $44.34
Previous CloseN/A
Volume273.50K
Average Volume (3M)924.70K
Market Cap
$2.20B
Enterprise Value$3.14B
Total Cash (Recent Filing)$717.15M
Total Debt (Recent Filing)$219.36M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Mar 03, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding111,962,810
10 Day Avg. Volume772,429
30 Day Avg. Volume924,704
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.08
Price to Sales (P/S)6.50
P/FCF Ratio-9.38
Enterprise Value/Market Cap1.43
Enterprise Value/Revenue7.10
Enterprise Value/Gross Profit11.59
Enterprise Value/Ebitda-16.90
Forecast
1Y Price Target
$54.02Price Target Upside170.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.51
Revenue Forecast (FY)$493.79M
Bulls Say, Bears Say
Bulls Say
CNS PenetrationZoci’s strong CNS penetration/activity, particularly in patients with untreated brain mets, is noteworthy, and appears to be a population excluded from competitor trials.
Efficacy MetricsZoci’s profile looks better than Imdelltra’s on key efficacy metrics.
Pipeline And ManagementThe company's broad pipeline of commercial and development-stage assets and a management team with extensive experience in the biopharma landscape contribute to a positive view on ZLAB.
Bears Say
Competitive BenchmarksThe stock was down mid-single digits over concerns around competitive benchmarks and the Ph3 control arm.
Extended TimelinesManagement increased sample size to retain power, apparently extending timelines.
Response DurabilityAlthough some competitors reported slightly better response rates than ZL-1310, there are uncertainties regarding the durability of responses and tolerability at potential dose levels.
Zai Lab News
ZLAB FAQ
What was Zai Lab’s price range in the past 12 months?
Zai Lab lowest stock price was $19.51 and its highest was $44.34 in the past 12 months.
What is Zai Lab’s market cap?
Zai Lab’s market cap is $2.20B.
When is Zai Lab’s upcoming earnings report date?
Zai Lab’s upcoming earnings report date is Mar 03, 2026 which is in 95 days.
How were Zai Lab’s earnings last quarter?
Zai Lab released its earnings results on Nov 06, 2025. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.289 by -$0.041.
Is Zai Lab overvalued?
According to Wall Street analysts Zai Lab’s price is currently Undervalued.
Does Zai Lab pay dividends?
Zai Lab does not currently pay dividends.
What is Zai Lab’s EPS estimate?
Zai Lab’s EPS estimate is -0.29.
How many shares outstanding does Zai Lab have?
Zai Lab has 111,962,810 shares outstanding.
What happened to Zai Lab’s price movement after its last earnings report?
Zai Lab reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.289. Following the earnings report the stock price went down -6.653%.
Which hedge fund is a major shareholder of Zai Lab?
Currently, no hedge funds are holding shares in ZLAB
Zai Lab Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.02 (170.51% Upside)
$54.02 (170.51% Upside)
Blogger Sentiment
Bullish
ZLAB Sentiment 75%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $289.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.51%
12-Months-Change
Fundamentals
Return on Equity
-28.96%
Trailing 12-Months
Asset Growth
17.62%
Trailing 12-Months
Company Description
Zai Lab
Zai Lab Limited is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, focused on discovering, developing, and commercializing innovative therapeutics for cancer and autoimmune diseases. The company operates primarily in the biotechnology sector and is dedicated to bringing novel therapies to patients in need. Zai Lab's core products include a range of drug candidates that target various oncology and autoimmune indications, leveraging its robust research and development capabilities.
ZLAB Company Deck
ZLAB Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook. Zai Lab showcased strong pipeline developments and success with VYVGART's market penetration in China. However, challenges such as slower commercial growth, supply constraints, and setbacks in the Bema program created significant headwinds. The company's focus on long-term growth and profitability remains strong.View all ZLAB earnings summariesZLAB Stock 12 Month Forecast
Average Price Target
$54.02
▲(170.51% Upside)
Technical Analysis
Ownership Overview
1.73% Insiders
12.91% Mutual Funds
18.10% Other Institutional Investors
66.45% Public Companies and
Individual Investors